JBM (Healthcare) Limited

SEHK:2161 Stock Report

Market Cap: HK$1.5b

JBM (Healthcare) Valuation

Is 2161 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2161 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2161 (HK$1.84) is trading below our estimate of fair value (HK$18.02)

Significantly Below Fair Value: 2161 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2161?

Key metric: As 2161 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2161. This is calculated by dividing 2161's market cap by their current earnings.
What is 2161's PE Ratio?
PE Ratio9.1x
EarningsHK$163.88m
Market CapHK$1.50b

Price to Earnings Ratio vs Peers

How does 2161's PE Ratio compare to its peers?

The above table shows the PE ratio for 2161 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average7.8x
2633 Jacobson Pharma
7.9xn/aHK$2.0b
2348 Dawnrays Pharmaceutical (Holdings)
3xn/aHK$1.8b
2566 Hangzhou Jiuyuan Gene Engineering
12.2xn/aHK$1.7b
239 Pak Fah Yeow International
7.9xn/aHK$760.4m
2161 JBM (Healthcare)
9.1xn/aHK$1.5b

Price-To-Earnings vs Peers: 2161 is expensive based on its Price-To-Earnings Ratio (9.1x) compared to the peer average (7.8x).

Price to Earnings Ratio vs Industry

How does 2161's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
858 Extrawell Pharmaceutical Holdings
0.6xn/aUS$14.45m
No more companies available in this PE range
2161 9.1xIndustry Avg. 8.4xNo. of Companies6PE0612182430+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2161 is expensive based on its Price-To-Earnings Ratio (9.1x) compared to the Hong Kong Pharmaceuticals industry average (8.4x).

Price to Earnings Ratio vs Fair Ratio

What is 2161's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2161 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2161's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 23:05
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

JBM (Healthcare) Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiao Qin DouUOB Kay Hian Research Pte Ltd
Gigi CheukUOB Kay Hian Research Pte Ltd